



Novel Therapies for the Treatment of Metastatic Prostate Cancer

Guest Editor:

Dr. Melissa LaBonte Wilson

Patrick G Johnston Centre for
Cancer Research, Queen's
University Belfast, Belfast, UK

Deadline for manuscript
submissions:

closed (22 February 2024)

Message from the Guest Editor

Dear Colleagues,

Prostate cancer remains one of the top cancers diagnosed in men worldwide.

In 2018–2019, anti-androgens abiraterone, apalutamide, and enzalutamide all received Federal Drug Administration (FDA) approval for metastatic castrate-sensitive prostate cancer (mCSPC). In addition, Relugolix, a highly selective oral gonadotropin-releasing hormone receptor antagonist, was approved for mCSPC based on the HERO (NCT03085095) trial results. Future research focuses on the interrogation and targeting of different molecular pathways, including PTEN-loss, DNA repair defects, autophagy, epigenetics, and inflammation, all with the potential for therapeutic intervention alone or in combination with approved agents. In addition, extensive research is underway to understand the immune context of prostate cancer and the identification of immune-based interventions. With the increased interrogation of genomic and molecular data, the list of novel therapies being investigated for metastatic prostate cancer remains vast.

In this Special Issue, we aim to highlight cutting-edge research on novel therapeutic agents and strategies for treating metastatic prostate cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com